Physician profile
Rena E Levykh-Chase
NPI 1215085360
$2,746.79
in general payments reported to CMS, 2019-2025
27 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $651 · 2021: $633 · 2022: $519 · 2023: $512 · 2024: $80.44 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $652.55 | 2019-2025 | Nucala, Shingrix, Trelegy Ellipta |
| Mylan Specialty L.P. | $336.35 | 2019-2023 | Yupelri |
| Lilly USA, LLC | $212.33 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $208.03 | 2019-2022 | |
| Novo Nordisk INC | $178.79 | 2019-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.84 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $159.96 | 2019-2023 | Farxiga |
| Exact Sciences Corporation | $137.83 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $131.89 | 2020-2023 | |
| Abbvie INC. | $129.94 | 2020-2022 | |
| Pfizer INC. | $72.87 | 2022-2024 | |
| Amarin Pharma, INC. | $43.01 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.15 | 2019-2020 | |
| Dynavax Technologies Corporation | $27.58 | 2021-2022 | |
| Grifols USA, LLC | $27.06 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.84 | 2020 | |
| Electromed, INC. | $25.77 | 2021-2022 | |
| Phadia US INC. | $22.78 | 2021 | |
| Shield Therapeutics INC | $20.34 | 2023 | Accrufer |
| Baxter Healthcare | $17.86 | 2025 | Hillrom - Monarch Airway Clearance System |
| Xeris Pharmaceuticals, INC. | $17.51 | 2023 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $15.27 | 2025 | Contrave |
| Boston Scientific Corporation | $14.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.79 | 2019 | |
| Astellas Pharma US INC | $13.42 | 2020 | |
| Allergan, INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Levykh-Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.